KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Other Working Capital Changes for 10 consecutive years, with -$229.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 56.87% year-over-year to -$229.0 million, compared with a TTM value of $1.4 billion through Dec 2025, up 143.93%, and an annual FY2025 reading of $1.4 billion, up 143.93% over the prior year.
  • Other Working Capital Changes was -$229.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $1.5 billion in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.5 billion in Q3 2025 and bottomed at -$1.7 billion in Q3 2021.
  • Average Other Working Capital Changes over 5 years is $29.8 million, with a median of -$1.5 million recorded in 2023.
  • The sharpest move saw Other Working Capital Changes plummeted 6290.0% in 2022, then soared 74950.0% in 2025.
  • Year by year, Other Working Capital Changes stood at $20.0 million in 2021, then tumbled by 6290.0% to -$1.2 billion in 2022, then surged by 94.26% to -$71.0 million in 2023, then crashed by 647.89% to -$531.0 million in 2024, then soared by 56.87% to -$229.0 million in 2025.
  • Business Quant data shows Other Working Capital Changes for TEVA at -$229.0 million in Q4 2025, $1.5 billion in Q3 2025, and -$606.0 million in Q2 2025.